Satsuma pharmaceuticals provides sts101 development program and corporate update

Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute...

December 20, 2022, 2:21 pm

Miromatrix's stock is down 33%

Shares of Miromatrix Medical Inc. were down about 33% in premarket trading on Thursday, the day after the company said there's a clinical hold on its ...

December 15, 2022, 8:35 am

Harrow health forges agreement to acquire exclusive us rights to blockbuster novartis eyecare drugs

Harrow Health Inc (NASDAQ:HROW) revealed that it has forged a binding agreement for the acquisition of the exclusive US commercial rights to five Food...

December 14, 2022, 12:07 pm

Ngm bio gives presentation featuring preclinical characterization of ngm936 at 2022 ash annual meeting

–NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells whi...

December 13, 2022, 12:00 am

Hca : should it be ready for next rally ?

HCA Healthcare, Inc., (HCA) provides health care services company in the United States. The company operates general & ...

December 12, 2022, 4:57 pm

Vincerx pharma presents preclinical data on vip943 in acute myeloid leukemia models at the 64th american society of hematology annual meeting 2022

Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with sign...

December 11, 2022, 3:05 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Syndax pharmaceuticals: today's best nearby biotech cap-gain prospect

How informed are you about binding interactions of Menin with the mixed lineage leukemia 1 protein for the treatment of ...

December 10, 2022, 3:11 am

Bionano genomics announces american society of hematology (ash) annual meeting presentations featuring ogm utility across blood cancer research applications

A scientific workshop will feature Dr. Rashmi Kanagal-Shamanna from the University of Texas MD Anderson Cancer Center delivering a presentation on the...

December 9, 2022, 1:24 am

Syndax's (sndx) leukemia drug gets fda breakthrough therapy tag

The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory ...

December 6, 2022, 9:47 am

Beam up as fda lifts clinical hold on the ind for beam-201

The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed/refractory T-cell ...

December 5, 2022, 12:48 pm

Rigel (rigl) up on fda nod to blood cancer drug rezlidhia

The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid...

December 2, 2022, 2:18 pm

Rigel pharmaceuticals (rigl) stock soars on fda approval news

Rigel Pharmaceuticals (NASDAQ: RIGL ) stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration (FDA) for it...

December 2, 2022, 11:17 am

Berkeley group: high-quality land bank to address london's acute housing shortage

Berkeley Group is a well-capitalized property developer with a strong market position in the London housing market. It has an attractive land bank wor...

November 25, 2022, 11:09 pm

Novartis (nvs) set to advance malaria drug into phase iii

Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with ...

November 24, 2022, 12:02 pm

Japan preliminary november pmi, manufacturing plunges to contraction, services on the edge

The manufacturing result is the lowest in 2 years

Commentary from the report:

“Activity at Japanese private sector firms declined for...

November 24, 2022, 12:35 am